CTOs on the Move

Candel Therapeutics

www.candeltx.com

 
Also known as Advantagene. Inc., we are a Massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our Gene Mediated Cytotoxic (GMCI™) platform and our rQNestin34.5 platform. GMCI™ is an "off-the-shelf"​ immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.candeltx.com
  • 117 Kendrick Street Suite 450
    Needham, MA USA 02494
  • Phone: 617.916.5445

Executives

Name Title Contact Details
Seshu Tyagarajan
Chief Technical and Development Officer Profile

Funding

Candel Therapeutics raised $22.5M on 04/01/2019
Candel Therapeutics raised $25M on 03/01/2022

Similar Companies

Celula Inc

Celula Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CARIS MPI

CARIS MPI is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bio Clean USA

Bio Clean USA is a Bridgeport, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RenovoRx

RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via our proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. Our lead product candidate, RenovoGem, is a combination of gemcitabine and our patented delivery system regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). Targeted therapy via RenovoTAMP platform safely and without transmission to non-targeted areas, is our primary focus. RenovoRx`s patent portfolio currently includes seven issued US patents and one European patent for ourtechnology with several additional patents pending in the US, Europe, and Asia. After demonstrating a median survival of 27.9 months in Phase 1/2 clinical trials vs. 12-15 months reported in historical studies for this patient population, RenovoRx secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine: pancreatic cancer and bile duct cancer (cholangiocarcinoma). This therapy is being further studied in the currently enrolling Phase 3 TIGeR-PaC clinical trial in pancreatic cancer and has a primary endpoint of overall survival and several secondary endpoints, including quality of life. The Phase 3 TIGeR-PaC clinical trial is enrolling unresectable locally advanced pancreatic cancer patients (LAPC) in the United States.

Epitopix

Epitopix LLC is a Willmar, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.